MKM Partners Initiated Stock Coverage on This BioPharma Company Today

Wall St. Watchdog reveals information about companies for which stock analysts initiated coverage on October 19th.

    • Bristol-Myers (NYSE:BMY): MKM Partners initiated coverage of this company with a rating of Sell and a price target of $26. About the company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet